pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
GILEAD · news · pharmadog
← back to GILEAD
News mentioning GILEAD
127
stories
22h
DPHARM: How to address the clinical trial enrollment crisis?
fiercebiotech
1d
Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO
endpoints
1d
Sionna says good-bye to 46% of staffers, including exec
biospace
2d
WCLC ‘26: A new ‘ADC era,’ China questions and AstraZeneca’s spotlight
biopharma dive
4d
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
fiercebiotech
4d
STAT+: Trump’s secretive pharma deals may undermine ‘most-favored nation’ pricing, an analysis suggests
stat
6d
STAT+: Pharma wins a battle over the cost of wastewater treatment in Europe
stat
6d
STAT+: Up and down the ladder: The latest comings and goings
stat
6d
STAT+: Pharmalittle: We’re reading about anxious Novartis investors, patent expirations for biologics, and more
stat
6d
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use
biopharma dive
7d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
7d
Platinum-based chemotherapy in childhood causes mutations that age the liver
stat
7d
STAT+: The gifts from pharma companies that keep on giving
stat
7d
Chutes & Ladders—Longtime Takeda R&D chief to depart next June
fiercebiotech
7d
STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more
stat
7d
STAT+: Cancer medicines remain in short supply across the U.S., survey finds
stat
7d
Tyra shares slip as bladder cancer responses fall short of investor expectations
biospace
8d
CEO O’Day tells Fierce how Gilead’s cancer, inflammation expansion has reached ‘critical mass’
fiercebiotech
8d
Compass posts positive psilocybin data; Solstice makes $225M debut
endpoints
8d
BMS clinches pivotal win for myeloma CAR T in ‘key derisking event’
biospace
13d
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
14d
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
17d
ArsenalBio sheds most of staff in pivot to in vivo CAR-T
fiercebiotech
17d
Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
fiercebiotech
20d
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
biopharma dive
21d
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
21d
Gilead gets another HIV treatment approval, extending lenacapavir's dominance
endpoints
21d
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
23d
Labcorp launches new hepatitis D test to find patients with most severe form of virus
fiercebiotech
28d
Chutes & Ladders—Neumora shuffles leadership ahead of IND
fiercebiotech
← prev
page 1 of 5
next →
